Related Experiment Video

Updated: Jun 25, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

New protein kinase CK2 inhibitors: jumping out of the catalytic box

Renaud Prudent1, Claude Cochet

  • 1INSERM U873, LTS, iRTSV, CEA 17, Rue des Martyrs, Grenoble, France. renaud.prudent@cea.fr

Chemistry & Biology
|February 28, 2009
PubMed

Insights

Protein kinase CK2, a cancer target, has new inhibitors that avoid the ATP-binding pocket. This review explores alternative strategies for CK2 inhibition, addressing selectivity concerns in cancer drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protein kinases are crucial in cell signaling and frequently dysregulated in cancer, making them key drug targets.
  • Current kinase inhibitors often target the ATP-binding pocket, leading to selectivity issues.
  • Protein kinase CK2 (Casein kinase 2) overexpression is linked to poor prognosis in various cancers, highlighting its therapeutic relevance.

Purpose of the Study:

  • To review emerging strategies for inhibiting protein kinase CK2.
  • To discuss novel CK2 inhibitors that do not compete with ATP.
  • To explore alternative therapeutic approaches beyond ATP-competitive inhibition for CK2.

Main Methods:

  • Literature review of scientific publications on protein kinase CK2 inhibitors.
  • Analysis of different classes of CK2 inhibitors, including ATP-competitive and non-ATP-competitive agents.
  • Discussion of the molecular architecture of CK2 and its implications for drug design.

Main Results:

  • Several classes of ATP-competitive CK2 inhibitors exist with variable efficacy.
  • Newer inhibitors acting through non-ATP-competitive mechanisms are emerging.
  • The unique structure of the CK2 enzyme presents opportunities for developing selective inhibitors.

Conclusions:

  • Targeting protein kinase CK2 is a promising strategy in cancer therapy.
  • Developing non-ATP-competitive inhibitors can overcome selectivity challenges associated with traditional kinase inhibitors.
  • Exploring alternative inhibition mechanisms based on CK2's molecular structure is crucial for effective cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...